https://www.siliconvalley.com/2021/01/29/johnson-johnson-covid-19-vaccine-is-66-effective-in-global-trial-but-85-effective-against-severe-disease-company-says/

Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% efficacy against severe disease, the company announced Friday.

The vaccine was 72% effective against moderate and severe disease in the US, the company said.